Trial Profile
A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2020
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Carcinoma; Liver metastases; Malignant thymoma; Thymic epithelial tumour; Thymoma
- Focus Therapeutic Use
- Acronyms TET-SEL
- 13 Apr 2018 Planned number of patients changed from 25 to 50.
- 19 Mar 2018 New trial record